Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES

(GILD)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • The company usually posts poor financials for mid or long term investments.
  • The company has poor fundamentals for a short-term investment strategy.
Strengths
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
  • According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Ratings chart
Sector Bio Therapeutic Drugs
1st jan.Capitalisation (M$)Investor Rating
GILEAD SCIENCES5.45%83 231
VERTEX PHARMACEUTICALS5.32%44 858
REGENERON PHARMACEUTICALS-23.68%31 192
GENMAB27.73%13 383
NEUROCRINE BIOSCIENCES, INC..41.60%9 261
HUALAN BIOLOGICAL ENGINEERI..--.--%6 546
SAREPTA THERAPEUTICS INC-23.33%6 220
BLUEBIRD BIO INC8.31%5 938
EXELIXIS, INC.-2.03%5 837
TONGHUA DONGBAO PHARMACEUTI..32.37%5 310
ASCENDIS PHARMA A/S64.98%4 914
SPARK THERAPEUTICS INC165.99%4 007
CHINA BIOLOGIC PRODUCTS HOL..35.87%3 947
BIOCON LTD-27.49%3 787
MIRATI THERAPEUTICS INC116.31%3 606
IDORSIA LTD54.87%3 325
More Results
Financials (USD)
Sales 2019 22 314 M
EBIT 2019 11 591 M
Net income 2019 4 272 M
Debt 2019 3 023 M
Yield 2019 3,82%
P/E ratio 2019 18,8x
P/E ratio 2020 11,5x
EV / Sales2019 3,88x
EV / Sales2020 3,74x
Capitalization 83 535 M
Upcoming event on GILEAD SCIENCES
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation -
Finances -
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes